Share: 
Status: 
Active
Rating: 
No votes yet
0

ECTRIMS 2016: Utilizing Individualized Treatment Plans to Optimally Manage Patients with Multiple Sclerosis

Course description

This CME program will focus on the new and emerging therapeutic options for the management of patients with multiple sclerosis (MS) that were discussed at the 2016 ECTRIMS Annual Meeting in London, United Kingdom from September 14 – 17, 2016. This activity will educate healthcare providers about novel techniques and optimal management strategies for their patients with multiple sclerosis. The expert faculty will discuss the science behind new and emerging therapies, the efficacy and safety data supporting new biomarkers, and the role of biomarkers alongside traditional MS treatment options. Upon completion of this CME activity, the multidisciplinary team will be equipped with the information needed to create tailored treatment plans and improve outcomes.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of neurologists, nurse practitioners, and other health care professionals involved in the diagnosis, treatment, or management of patients with MS.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be able to:

  1. Discuss current science of multiple sclerosis as presented at ECTRIMS 2016.

  2. Analyze clinical trial data presented at ECTRIMS 2016.
  3. Apply updated data to the treatment of patients with multiple sclerosis.

FACULTY

Mark Freedman, MD
Professor of Medicine
University of Ottawa
Senior Scientist
Ottawa Hospital Research Institue
Ottawa, Ontario, Canada

Fred Lublin, MD
Saunders Family Professor of Neurology
Director, The Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, NY

Per Soelberg Sørensen, MD
Professor of Neurology
Copenhagen University
Director, Danish Multiple Sclerosis Center, Rigshospitalet
Copenhagen, Denmark

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
Mark Freedman, MD

Consultant/Advisor: Actelion Pharmaceuticals US, Inc.; Bayer AG; Biogen; Chugai Pharmaceutical Co., Ltd.; EMD Serono, Inc.; Genzyme Corporation; Hoffmann-La Roche, Ltd.; Novartis AG; Opexa Therapeutics, Inc.; sanofi-aventis U.S. LLC; Teva Canada Innovation

Speaker's Bureau: Genzyme Corporation

Fred D. Lublin, MD

Consultant/Advisor: Actelion Pharmaceuticals US, Inc.; Acorda Therapeutics; Akros Pharma Inc.; Bayer AG; BBB Therapeutics; Biogen; Celgene Corporation;  EMD Serono, Inc.; Forward Pharma; Genentech, Inc.; Genzyme Corporation; Mallinckrodt; MedImmune; Novartis AG; Osmotica Pharmaceutical Corp.;  Receptos, Inc.; Hoffmann-La Roche, Ltd.; Sanofi; Teva Pharmaceutical Industries, Ltd.; XenoPort, Inc.

Grant/Research Support: Biogen; Celgene Corporation; Genzyme Corporation; National Institutes of Health; Novartis AG; Teva Pharmaceutical Industries, Ltd.; Transparency Life Sciences

Stock Ownership: Cognition Pharmaceuticals, Inc.

Per Soelberg Sørensen, MD

Consultant/Advisor: Biogen; Forward Pharma; Genzyme Corporation; Emd Serono, Inc.; Novartis AG; Teva Pharmaceutical Industries, Ltd.

Non-faculty: Sandy Breslow; Alison Kemp; Leah Johnson; Bernard M. Abrams, MD; Timothy Hayes, MD, PhD; Emma Gilmartin; Nicole Brestowski; and Megan Gentile hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months. 

Financial Support

This CME activity has been supported by an independent educational grant from Biogen.

Provider Information

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.

CME Credit (Physicians)

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME, and Biogen do not recommend the use of any agent outside of the labeled indications.

Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Credits & accreditation
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
12/20/2016
Course expires: 
12/19/2017
Please login or register to take this course.